BEIZRAY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Beizray, and what generic alternatives are available?
Beizray is a drug marketed by Zhuhai and is included in one NDA.
The generic ingredient in BEIZRAY is docetaxel. There are forty-one drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the docetaxel profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Beizray
A generic version of BEIZRAY was approved as docetaxel by HOSPIRA INC on March 8th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BEIZRAY?
- What are the global sales for BEIZRAY?
- What is Average Wholesale Price for BEIZRAY?
Summary for BEIZRAY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in BEIZRAY? | BEIZRAY excipients list |
| DailyMed Link: | BEIZRAY at DailyMed |
US Patents and Regulatory Information for BEIZRAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zhuhai | BEIZRAY | docetaxel | SOLUTION;INTRAVENOUS | 218711-001 | Oct 23, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
